InSilico Medicine Cayman TopCo
3696Biotechnology
HK$36.62−2.66%As of Oct 29vs prior close
- Market cap
- $2.7B
- P/E (TTM)
- –
- P/E (FY1)
- 34.5×
- From 52W high
- −52.38%
- EPS (TTM)
- –
- Revenue (LTM)
- $135.1M
- Net margin
- -220.28%
Nomior Score
47
Steady ProfileBottom 43% of the scored universe
Growth—
Quality53
Value53
Momentum—
Resilience38
Growth
+23.10%revenue a year over 3 fiscal years
YE22 $30.1MLTM $135.1M
Connections
Revenue to profitYE25
The net loss was 626% of revenue, wider by 607 pts on a year.